MIRA Pharmaceuticals Stock (NASDAQ:MIRA)


OwnershipFinancialsChart

Previous Close

$1.85

52W Range

$0.51 - $6.40

50D Avg

$1.37

200D Avg

$1.20

Market Cap

$27.64M

Avg Vol (3M)

$2.09M

Beta

6.73

Div Yield

-

MIRA Company Profile


MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.

Show More

Industry

Drug Manufacturers - General

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

2

IPO Date

Aug 14, 2023

Website

MIRA Performance


MIRA Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-16.60M$-7.05M$-2.15M
Net Income$-11.98M$-7.06M$-2.18M
EBITDA$-16.60M$-7.05M$-2.15M
Basic EPS$-0.65$-0.48$-0.15
Diluted EPS$-0.65$-0.48$-0.15

Fiscal year ends in Dec 23 | Currency in USD